Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
Epistemonikos ID: c77dad4825eefe7431fd0edfdbe37b2d505f2450
First added on: May 09, 2024